LPCN News and Press, Lipocine Inc. From 05/12/22

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results PR Newswire LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Obser...

Lipocine press release (NASDAQ:LPCN): Q1 GAAP EPS of -$0.04 misses by $0.02. As of March 31, 2022, the company had $42.0 million of unrestricted cash, cash equivalents and marketable investment securities compared to $46.6 million as of December 31, 2021. Shares +1.3% PM. For further d...

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022 PR Newswire SALT LAKE CITY , May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendo...

LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS PR Newswire Industry veterans Jill M. Jene , Ph.D. and Spyros Papapetropoulos M.D. Ph.D. appointed to Board SALT LAKE CITY , April 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a b...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Seanergy Maritime Holdings ( SHIP ): Dry bulk goods shipper with rising share price and growing fleet. Charah Solutions ( CHRA ): 50% upside in coal plant remediation stock. Lipocine ( LPCN ): Li...

Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...

NeoGenomics (NEO) -29% on Q1 guidance cut; CEO to quit Progenity (PROG) -22% on Q4 earnings release. Stryve Foods (SNAX) -21% releases inaugural shareholder report. Kala Pharmaceuticals (KALA) -19% on Q4 earnings release. Lipocine (LPCN) -15% its partne...

LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™ PR Newswire Commercial launch expected in 2Q 2022 SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Shares of Lipocine Inc. (NASDAQ:LPCN) traded today at $1.75, eclipsing its 52-week high. This new high was reached on approximately average trading volume as 767,000 shares traded hands, while the average 30-day volume is approximately 722,000 shares. Lipocine Inc. (NASDAQ:LPCN) defies a...